Valuation: Viyash Scientific Limited

Market Cap 103B 1.06B 949M 885M 805M 1.51B 1.53B 10.61B 4.15B 52.5B 3.99B 3.91B 168B P/E 2027 *
33.7x
P/E 2028 * 20.3x
Enterprise Value 103B 1.06B 949M 885M 805M 1.51B 1.53B 10.61B 4.15B 52.5B 3.99B 3.91B 168B EV / Sales 2027 *
2.64x
EV / Sales 2028 * 2.31x
Free-Float
44.39%
Yield 2027 *
-
Yield 2028 * -
1 day-2.03%
1 week+0.06%
Current month+0.06%
1 month-10.50%
3 months-15.41%
6 months+20.81%
Current year+13.38%
1 week 228.2
Extreme 228.2
250.95
1 month 226.3
Extreme 226.3
263.15
Current year 178.4
Extreme 178.4
297.9
1 year 178.4
Extreme 178.4
297.9
3 years 90.85
Extreme 90.85
297.9
5 years 61.8
Extreme 61.8
297.9
10 years 42.45
Extreme 42.45
336.4
Manager TitleAgeSince
Chief Executive Officer 62 2025-12-15
Director of Finance/CFO - 2025-12-31
Chief Tech/Sci/R&D Officer - 2026-02-04
Director TitleAgeSince
Chairman 78 2025-08-24
Director/Board Member 67 2020-08-24
Director/Board Member 57 2022-04-10
Change 5-day change 1-year change 3-year change Capi.($)
-2.03%+0.06%+16.37%+150.00% 1.09B
-1.61%+1.08%+38.64%+106.93% 1,060B
-0.76%-3.12%+35.78%+62.70% 623B
+0.39%+4.14%+17.00%+83.77% 480B
-0.29%-2.02%+62.52%+37.06% 352B
-2.03%+1.03%+22.25%+42.16% 345B
-1.92%-1.87%+11.94%+33.20% 274B
-2.36%-3.16%-6.95%+8.68% 249B
-1.37%-3.34%+37.86%+52.33% 223B
+0.17%-1.31%+25.96%+96.82% 182B
Average -1.23%-0.22%+26.14%+67.36% 378.91B
Weighted average by Cap. -0.79%+0.04%+30.57%+68.85%

Financials

2027 *2028 *
Net sales 38.99B 403M 359M 335M 305M 573M 579M 4.02B 1.57B 19.87B 1.51B 1.48B 63.6B 44.68B 462M 412M 384M 349M 657M 664M 4.6B 1.8B 22.77B 1.73B 1.7B 72.88B
Net income 3.44B 35.53M 31.67M 29.54M 26.86M 50.56M 51.07M 354M 139M 1.75B 133M 130M 5.61B 5.4B 55.75M 49.7M 46.36M 42.15M 79.33M 80.13M 556M 217M 2.75B 209M 205M 8.8B
Net Debt - -
Projected Income Statement - Annual - Viyash Scientific Limited
Logo Viyash Scientific Limited
Viyash Scientific Limited, formerly SeQuent Scientific Limited, is an India-based integrated pharmaceutical company with a global footprint, operating in the domains of animal health (active pharmaceutical ingredients (APIs), and finished dosage formulations) and analytical services. The Company has eight manufacturing facilities, based in India, Turkey, Brazil, Spain and Germany. It is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It specializes in analytical and bioanalytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It offers analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer-developed methods or in-house method development.
Employees
2,900
Date Price Change Volume
26-10-08 ₹236.00 -2.03% 156,126
26-10-07 ₹240.90 +3.17% 214,027
26-10-06 ₹233.50 +1.85% 108,805
26-10-05 ₹229.25 -1.10% 75,806
26-10-01 ₹231.80 -1.72% 196,550
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Viyash Scientific Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
236.00INR
Average target price
322.25INR
Spread / Average Target
+36.55%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Viyash Scientific Limited
  1. Stock Market
  2. Stocks
  3. VIYASH Stock